Insider Selling: Establishment Labs Holdings Inc. (NASDAQ:ESTA) CEO Sells 3,641 Shares of Stock

Establishment Labs Holdings Inc. (NASDAQ:ESTA) CEO Quiros Juan Jose Chacon sold 3,641 shares of Establishment Labs stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $45.04, for a total value of $163,990.64. Following the completion of the transaction, the chief executive officer now owns 210,735 shares of the company’s stock, valued at $9,491,504.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Quiros Juan Jose Chacon also recently made the following trade(s):

• On Monday, July 8th, Quiros Juan Jose Chacon sold 3,866 shares of Establishment Labs stock. The shares were sold at an average price of $45.01, for a total transaction of $174,008.66.
• On Monday, July 1st, Quiros Juan Jose Chacon sold 6,839 shares of Establishment Labs stock. The shares were sold at an average price of $45.30, for a total transaction of $309,806.70.

Establishment Labs Stock Performance

Establishment Labs stock opened at $45.63 on Friday. Establishment Labs Holdings Inc. has a fifty-two week low of $16.96 and a fifty-two week high of $73.00. The stock’s fifty day moving average is $49.29 and its two-hundred day moving average is $44.55. The company has a debt-to-equity ratio of 3.38, a current ratio of 4.24 and a quick ratio of 2.73.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.58) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.07. The firm had revenue of $37.17 million for the quarter, compared to analysts’ expectations of $35.61 million. Establishment Labs had a negative net margin of 53.12% and a negative return on equity of 206.05%. The firm’s revenue was down 20.1% on a year-over-year basis. During the same period in the prior year, the company earned ($0.48) EPS. Sell-side analysts forecast that Establishment Labs Holdings Inc. will post -1.79 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ESTA has been the topic of several research analyst reports. Citigroup cut their price target on Establishment Labs from $60.00 to $50.00 and set a “neutral” rating on the stock in a research report on Wednesday. Mizuho raised their target price on shares of Establishment Labs from $65.00 to $70.00 and gave the stock a “buy” rating in a research note on Thursday, June 6th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, Establishment Labs has an average rating of “Moderate Buy” and an average target price of $54.00.

Institutional Investors Weigh In On Establishment Labs

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. American Century Companies Inc. lifted its position in Establishment Labs by 1.4% during the third quarter. American Century Companies Inc. now owns 282,292 shares of the company’s stock valued at $13,852,000 after buying an additional 3,831 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of Establishment Labs during the 4th quarter valued at about $120,000. FNY Investment Advisers LLC acquired a new stake in Establishment Labs during the fourth quarter worth about $93,000. Legato Capital Management LLC lifted its holdings in Establishment Labs by 63.1% in the fourth quarter. Legato Capital Management LLC now owns 8,438 shares of the company’s stock worth $218,000 after acquiring an additional 3,263 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its stake in Establishment Labs by 357.7% in the fourth quarter. Assenagon Asset Management S.A. now owns 30,247 shares of the company’s stock valued at $783,000 after acquiring an additional 23,639 shares during the period. Hedge funds and other institutional investors own 72.91% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.